16 results on '"Claassen Y.H.M."'
Search Results
2. International comparison of treatment strategy and survival in metastatic gastric cancer
- Author
-
Claassen, Y.H.M., Bastiaannet, E., Hartgrink, H.H., Dikken, J.L., Steur, W.O. de, Slingerland, M., Verhoeven, R.H.A., Eycken, E. van, Schutter, H. de, Lindblad, M., Hedberg, J., Johnson, E., Hjortland, G.O., Jensen, L.S., Larsson, H.J., Koessler, T., Chevallay, M., Allum, W.H., Velde, C.J.H. van de, Oncology, and CCA - Cancer Treatment and Quality of Life
- Subjects
Adult ,Aged, 80 and over ,Male ,Cancer och onkologi ,Antineoplastic Agents ,Original Articles ,Middle Aged ,Survival Analysis ,Drug Utilization ,Europe ,Gastrectomy ,Stomach Neoplasms ,Cancer and Oncology ,Humans ,Original Article ,Female ,Registries ,Neoplasm Metastasis ,Aged - Abstract
Background: In the randomized Asian REGATTA trial, no survival benefit was shown for additional gastrectomy over chemotherapy alone in patients with advanced gastric cancer with a single incurable factor, thereby discouraging surgery for these patients. The purpose of this study was to evaluate treatment strategies for patients with metastatic gastric cancer in daily practice in five European countries, along with relative survival in each country. Methods: Nationwide population‐based data from Belgium, Denmark, the Netherlands, Norway and Sweden were combined. Patients with primary metastatic gastric cancer diagnosed between 2006 and 2014 were included. The proportion of gastric resections performed and the administration of chemotherapy (irrespective of surgery) within each country were determined. Relative survival according to country was calculated. Results: Overall, 15 057 patients with gastric cancer were included. The proportion of gastric resections varied from 8·1 per cent in the Netherlands and Denmark to 18·3 per cent in Belgium. Administration of chemotherapy was 39·2 per cent in the Netherlands, compared with 63·2 per cent in Belgium. The 6‐month relative survival rate was between 39·0 (95 per cent c.i. 37·8 to 40·2) per cent in the Netherlands and 54·1 (52·1 to 56·9) per cent in Belgium. Conclusion: There is variation in the use of gastrectomy and chemotherapy in patients with metastatic gastric cancer, and subsequent differences in survival.
- Published
- 2019
- Full Text
- View/download PDF
3. Quality assurance in the surgical treatment of gastric cancer
- Author
-
Claassen, Y.H.M., Velde, C.J.H. van de, Hartgrink, H.H., Putter, H., Portielje, J.E.A., Rosman, C., Gisbertz, S.S., and Leiden University
- Subjects
Treatment strategy ,Survival ,Surgery ,Gastric cancer ,Metastatic gastric cancer ,Quality assurance ,Surgical quality ,Hospital volume - Abstract
This thesis focus on the quality assurance in the surgical treatment of gastric cancer. This has been investigated using data of the CRITICS trial. In this randomized clinical patients underwent preoperative chemotherapy, followed by surgery, followed by adjuvant chemotherapy or chemoradiotherapy. Surgical quality in the CRITICS trial was investigated and was excellent (PART I). Furthermore, the influence of hospital volume on surgical quality and survival was analyzed using data of the CRITICS trial (PART II). Surgery performed in hospitals with high hospital volume was associated with better surgical quality and better survival. In part III of this thesis analyses were performed to analyze treatment strategy and survival in patients with resectable gastric cancer and in patients with metastatic gastric cancer.
- Published
- 2018
4. Patterns of Recurrence in the Critics Gastric Cancer Trial: Results from Intention-to-Treat and per-Protocol Analyses
- Author
-
van Amelsfoort, R.M., primary, de Steur, W., additional, Sikorska, K., additional, Jansen, E.P.M., additional, Cats, A., additional, van Grieken, N.C., additional, Boot, H., additional, Lind, P.A., additional, Meershoek-Klein Kranenbarg, E., additional, Nordsmark, M., additional, Hartgrink, H., additional, Putter, H., additional, Trip, A.K., additional, Sandick, J.W., additional, van Tinteren, H., additional, Claassen, Y.H.M., additional, Braak, J.P.B.M., additional, van Laarhoven, H.W., additional, van de Velde, C.J., additional, and Verheij, M., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Time trends of short-term mortality for octogenarians undergoing a colorectal resection in North Europe
- Author
-
Claassen, Y.H.M., primary, Bastiaannet, E., additional, van Eycken, E., additional, Van Damme, N., additional, Martling, A., additional, Johansson, R., additional, Iversen, L.H., additional, Ingeholm, P., additional, Lemmens, V.E.P.P., additional, Liefers, G.J., additional, Holman, F.A., additional, Dekker, J.W.T., additional, Portielje, J.E.A., additional, Rutten, H.J., additional, and van de Velde, C.J.H., additional
- Published
- 2019
- Full Text
- View/download PDF
6. Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial
- Author
-
Claassen, Y.H.M., Hartgrink, H.H., Steur, W.O. de, Dikken, J.L., Sandick, J.W. van, Grieken, N.C. van, Cats, A., Trip, A.K., Jansen, E.P.M., Kranenbarg, W.M.M., Braak, J., Putter, H., Henegouwen, M.I. van Berge, Verheij, M., Velde, C.J. van de, Claassen, Y.H.M., Hartgrink, H.H., Steur, W.O. de, Dikken, J.L., Sandick, J.W. van, Grieken, N.C. van, Cats, A., Trip, A.K., Jansen, E.P.M., Kranenbarg, W.M.M., Braak, J., Putter, H., Henegouwen, M.I. van Berge, Verheij, M., and Velde, C.J. van de
- Abstract
Contains fulltext : 203168.pdf (publisher's version ) (Open Access), BACKGROUND: Preoperative randomization for postoperative treatment might affect quality of surgery. In the CRITICS trial (ChemoRadiotherapy after Induction chemotherapy In Cancer of the Stomach), patients were randomized before treatment to receive chemotherapy prior to a D1 + gastrectomy (removal of lymph node station (LNS) 1-9 + 11), followed by either chemotherapy (CT) or chemoradiotherapy (CRT). In this analysis, the influence of upfront randomization on the quality of surgery was evaluated. METHODS: Quality of surgery was analyzed in both study arms using surgicopathological compliance (removal of >/= 15 lymph nodes), surgical compliance (removal of the indicated LNS), and surgical contamination (removal of LNS that should be left in situ). Furthermore, the 'Maruyama Index of Unresected disease' (MI) was evaluated in both study arms, and validated with overall survival. RESULTS: Between 2007 and 2015, 788 patients with gastric cancer were included in the CRITICS study of which 636 patients were operated with curative intent. No difference was observed between the CT and CRT group regarding surgicopathological compliance (74.8% vs 70.9%, P = 0.324), surgical compliance (43.2% vs 39.2%, P = 0.381), and surgical contamination (59.4% vs 59.9%, P = 0.567). Median MI was 1 in both groups (range CT 0-88 and CRT 0-136, P = 0.700). A MI below 5 was associated with better overall survival (CT: P = 0.009 and CRT: P = 0.013). CONCLUSION: Surgical quality parameters were similar in both study arms in the CRITICS gastric cancer trial, indicating that upfront randomization for postoperative treatment had no impact on the quality of surgery. A Maruyama Index below five was associated with better overall survival.
- Published
- 2019
7. Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival Results From the CRITICS Trial
- Author
-
Claassen, Y.H.M., Amelsfoort, R.M. van, Hartgrink, H.H., Dikken, J.L., Steur, W.O. de, Sandick, J.W. van, Verheij, M., Velde, C.J. van de, Claassen, Y.H.M., Amelsfoort, R.M. van, Hartgrink, H.H., Dikken, J.L., Steur, W.O. de, Sandick, J.W. van, Verheij, M., and Velde, C.J. van de
- Abstract
Item does not contain fulltext
- Published
- 2019
8. North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis
- Author
-
Claassen, Y.H.M., primary, Dikken, J.L., additional, Hartgrink, H.H., additional, de Steur, W.O., additional, Slingerland, M., additional, Verhoeven, R.H.A., additional, van Eycken, E., additional, de Schutter, H., additional, Johansson, J., additional, Rouvelas, I., additional, Johnson, E., additional, Hjortland, G.O., additional, Jensen, L.S., additional, Larsson, H.J., additional, Allum, W.H., additional, Portielje, J.E.A., additional, Bastiaannet, E., additional, and van de Velde, C.J.H., additional
- Published
- 2018
- Full Text
- View/download PDF
9. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial
- Author
-
Claassen, Y.H.M., primary, Hartgrink, H.H., additional, Dikken, J.L., additional, de Steur, W.O., additional, van Sandick, J.W., additional, van Grieken, N.C.T., additional, Cats, A., additional, Trip, A.K., additional, Jansen, E.P.M., additional, Meershoek-Klein Kranenbarg, W.M., additional, Braak, J.P.B.M., additional, Putter, H., additional, van Berge Henegouwen, M.I., additional, Verheij, M., additional, and van de Velde, C.J.H., additional
- Published
- 2018
- Full Text
- View/download PDF
10. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial
- Author
-
Claassen, Y.H.M., Hartgrink, H.H., Dikken, J.L., Steur, W.O. de, Sandick, J.W. van, Grieken, N.C. van, Cats, A., Trip, A.K., Jansen, E.P.W.A., Meershoek-Klein Kranenbarg, W.M., Braak, J., Putter, H., Berge Henegouwen, M.I. van, Verheij, M., Velde, C.J. van de, Claassen, Y.H.M., Hartgrink, H.H., Dikken, J.L., Steur, W.O. de, Sandick, J.W. van, Grieken, N.C. van, Cats, A., Trip, A.K., Jansen, E.P.W.A., Meershoek-Klein Kranenbarg, W.M., Braak, J., Putter, H., Berge Henegouwen, M.I. van, Verheij, M., and Velde, C.J. van de
- Abstract
Item does not contain fulltext, BACKGROUND: In order to determine the optimal combination of perioperative chemotherapy and chemoradiotherapy for Western patients with advanced resectable gastric cancer, the international multicentre CRITICS trial (ChemoRadiotherapy after Induction chemotherapy In Cancer of the Stomach) was initiated. In this trial, patients with resectable gastric cancer were randomised before start of treatment between adjuvant chemotherapy or adjuvant chemoradiotherapy following neoadjuvant chemotherapy plus gastric cancer resection. The purpose of this study was to report on surgical morbidity and mortality in this trial, and to identify factors associated with surgical morbidity. METHODS: Patients who underwent a gastrectomy with curative intent were selected. Logistic regression analyses were used to assess risk factors for developing postoperative complications. RESULTS: Between 2007 and 2015, 788 patients were included in the CRITICS trial, of whom 636 patients were eligible for current analyses. Complications occurred in 296 patients (47%). Postoperative mortality was 2.2% (n = 14). Complications due to anastomotic leakage was cause of death in 5 patients. Failure to complete preoperative chemotherapy (OR = 2.09, P = 0.004), splenectomy (OR = 2.82, P = 0.012), and male sex (OR = 1.55, P = 0.020) were associated with a greater risk for postoperative complications. Total gastrectomy and oesophago-cardia resection were associated with greater risk for morbidity compared with subtotal gastrectomy (OR = 1.88, P = 0.001 and OR = 1.89, P = 0.038). CONCLUSION: Compared to other Western studies, surgical morbidity in the CRITICS trial was slightly higher whereas mortality was low. Complications following anastomotic leakage was the most important factor for postoperative mortality. Important proxies for developing postoperative complications were failure to complete preoperative chemotherapy, splenectomy, male sex, total gastrectomy, and oesophago-cardia resection.
- Published
- 2018
11. Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial
- Author
-
Claassen, Y.H.M., Steur, W.O. de, Hartgrink, H.H., Dikken, J.L., Sandick, J.W. van, Grieken, N.C. van, Cats, A., Trip, A.K., Jansen, E.P.M., Kranenbarg, W.M.M., Braak, J., Putter, H., Berge Henegouwen, M.I. van, Verheij, M., Velde, C.J. van de, Claassen, Y.H.M., Steur, W.O. de, Hartgrink, H.H., Dikken, J.L., Sandick, J.W. van, Grieken, N.C. van, Cats, A., Trip, A.K., Jansen, E.P.M., Kranenbarg, W.M.M., Braak, J., Putter, H., Berge Henegouwen, M.I. van, Verheij, M., and Velde, C.J. van de
- Abstract
Item does not contain fulltext, OBJECTIVE: The purpose of this study was to evaluate surgicopathological quality and protocol adherence for lymphadenectomy in the CRITICS trial. SUMMARY OF BACKGROUND DATA: Surgical quality assurance is a key element in multimodal studies for gastric cancer. In the multicenter CRITICS trial (ChemoRadiotherapy after Induction chemotherapy In Cancer of the Stomach), patients with resectable gastric cancer were randomized for preoperative chemotherapy, followed by gastrectomy with a D1+ lymphadenectomy (removal of stations 1 to 9 and 11), followed by either chemotherapy or chemoradiotherapy. METHODS: Surgicopathological compliance was defined as removal of >/=15 lymph nodes. Surgical compliance was defined as removal of the indicated lymph node stations. Surgical contamination was defined as removal of lymph node stations that should be left in situ. The Maruyama Index (MI, lower is better), which has proven to be an indicator of surgical quality and is strongly associated with survival, was analyzed. RESULTS: Between 2007 and 2015, 788 patients were randomized, of whom 636 patients underwent a gastrectomy with curative intent. Surgicopathological compliance occurred in 72.8% (n = 460) of the patients and improved from 55.0% (2007) to 90.0% (2015). Surgical compliance occurred in 41.1% (n = 256). Surgical contamination occurred in 59.6% (n = 371). Median MI was 1 (range 0 to 136). CONCLUSION: Surgical quality in the CRITICS trial was excellent, with a MI of 1. Surgicopathological compliance improved over the years. This might be explained by the quality assurance program within the study and centralization of gastric cancer surgery in the Netherlands.
- Published
- 2018
12. Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial
- Author
-
Claassen, Y.H.M., Sandick, J.W. van, Hartgrink, H.H., Dikken, J.L., Steur, W.O. de, Grieken, N.C. van, Boot, H., Cats, A., Trip, A.K., Jansen, E.P.M., Meershoek-Klein Kranenbarg, W.M., Braak, J., Putter, H., Berge Henegouwen, M.I. van, Verheij, M., Velde, C.J. van de, Claassen, Y.H.M., Sandick, J.W. van, Hartgrink, H.H., Dikken, J.L., Steur, W.O. de, Grieken, N.C. van, Boot, H., Cats, A., Trip, A.K., Jansen, E.P.M., Meershoek-Klein Kranenbarg, W.M., Braak, J., Putter, H., Berge Henegouwen, M.I. van, Verheij, M., and Velde, C.J. van de
- Abstract
Item does not contain fulltext, BACKGROUND: Studies investigating the association between hospital volume and quality of gastric cancer surgery are lacking. In the present study, the effect of hospital volume on quality of gastric cancer surgery was evaluated by analysing data from the CRITICS (ChemoRadiotherapy after Induction chemotherapy In Cancer of the Stomach) trial. METHODS: Patients who underwent gastrectomy with curative intent in the Netherlands were selected from the CRITICS trial database. Annual hospital volume of participating centres was derived from the Netherlands Cancer Registry. Hospital volume was categorized into very low (1-10 gastrectomies per year per institution), low (11-20), medium (21-30) and high (31 or more), and linked to the CRITICS database. Quality of surgery was analysed by surgicopathological compliance (removal of at least 15 lymph nodes), surgical compliance (removal of indicated lymph node stations) and the Maruyama Index. Postoperative morbidity and mortality were also compared between hospital categories. RESULTS: Between 2007 and 2015, 788 patients were included in the CRITICS study, of whom 494 were analysed. Surgicopathological compliance was higher (86.7 versus 50.4 per cent; P < 0.001), surgical compliance was greater (52.9 versus 19.8 per cent; P < 0.001) and median Maruyama Index was lower (0 versus 6; P = 0.006) in high-volume hospitals compared with very low-volume hospitals. There was no statistically significant difference in postoperative complications or mortality between the hospital volume categories. CONCLUSION: Surgery performed in high-volume hospitals was associated with better surgical quality than surgery carried out in lower-volume hospitals.
- Published
- 2018
13. Surgicopathological quality control in the CRITICS gastric cancer trial
- Author
-
Claassen, Y.H.M., primary, De Steur, W.O., additional, Hartgrink, H.H., additional, Van Sandick, J.W., additional, Dikken, J.L., additional, Meershoek-Klein Kranenberg, E., additional, Braak, J., additional, Jansen, E.P.M., additional, Van Grieken, N.C.T., additional, Putter, H., additional, Trip, A., additional, Boot, H., additional, Cats, A., additional, Sikorska, K., additional, Van Tinteren, H., additional, Verheij, M., additional, and Van de Velde, C.J.H., additional
- Published
- 2017
- Full Text
- View/download PDF
14. 78. Surgicopathological quality control in the CRITICS gastric cancer trial
- Author
-
Claassen, Y.H.M., primary, De Steur, W.O., additional, Dikken, J.L., additional, Hartgrink, H.H., additional, Jansen, E.P.M., additional, Trip, A.K., additional, Van Grieken, N.C.T., additional, Putter, H., additional, Meershoek – Klein Kranenberg, E., additional, Van Sandick, J.W., additional, Boot, H., additional, Cats, A., additional, Aaronson, N.K., additional, Sikorska, K., additional, Van Tinteren, H., additional, Verheij, M., additional, and Van de Velde, C.J.H., additional
- Published
- 2016
- Full Text
- View/download PDF
15. 7BA - Surgicopathological quality control in the CRITICS gastric cancer trial
- Author
-
Claassen, Y.H.M., De Steur, W.O., Hartgrink, H.H., Van Sandick, J.W., Dikken, J.L., Meershoek-Klein Kranenberg, E., Braak, J., Jansen, E.P.M., Van Grieken, N.C.T., Putter, H., Trip, A., Boot, H., Cats, A., Sikorska, K., Van Tinteren, H., Verheij, M., and Van de Velde, C.J.H.
- Published
- 2017
- Full Text
- View/download PDF
16. Years of Life Lost for Older Patients After Colorectal Cancer Diagnosis
- Author
-
Y.H.M. Claassen, Amanda C R K Bos, Esther Bastiaannet, Giorgio Ercolani, Jan Willem T. Dekker, Alessandro Cucchetti, Federico Mazzotti, Mazzotti F., Cucchetti A., Claassen Y.H.M., Bos A.C.R.K., Bastiaannet E., Ercolani G., and Dekker J.W.T.
- Subjects
Male ,medicine.medical_specialty ,Prognosi ,Population ,Colorectal Neoplasm ,Comorbidity ,03 medical and health sciences ,0302 clinical medicine ,Life Expectancy ,Internal medicine ,Medicine ,Humans ,Life Tables ,education ,Neoplasm Staging ,Aged, 80 and over ,education.field_of_study ,Life Table ,business.industry ,Incidence (epidemiology) ,Vascular surgery ,medicine.disease ,Prognosis ,Years of potential life lost ,030220 oncology & carcinogenesis ,Cohort ,Number needed to treat ,030211 gastroenterology & hepatology ,Surgery ,Female ,business ,Colorectal Neoplasms ,Human ,Abdominal surgery ,Numbers Needed To Treat - Abstract
Background: An aging population combined with an increased colorectal cancer (CRC) incidence in the older population will increase its prevalence in the elderly, questioning how many years of life are lost (YLLs) in these patients. Patients and methods: Data from 32,568 Dutch CRC patients ≥ 80years were used to estimate the number of YLLs after diagnosis, using a reference age-, sex- and year-of-onset-matched cohort derived from national life tables. YLLs were additionally adjusted by comorbidities. Number needed to treat (NNT) was used as measure of surgical effect size. Results: Surgery was applied in 74.9% of patients leading to 1.3 YLLs, being superior in 86.1% of cases with respect to alternative therapies (YLLs 4.8years) and resulting in a number of two patients needed to operate to achieve one positive outcome. YLLs and NNTs depended on CRC stage, patient’ age and comorbidities. For Stage I–II patients in the best clinical conditions (80–85years without comorbidities), YLLs increased up to 4.1years after surgery and up to 8.8years without surgery (NNT 3). For Stage III patients, the NNT of surgery varied between 2 when they were in the best clinical conditions and 4 when they were older with high comorbidities. In Stage IV patients, the NNT ranged between 6 and 31. Conclusions: YLLs represents a novel approach to evaluate CRC prognosis. Stage I–III surgical patients can have a life expectancy similar to that of general population, being the NNT of surgery reasonably small compared with alternatives. Personalized comorbidity data are needed to confirm present findings.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.